| Name | MEISi-2 |
| Description | MEISi-2 is a specific MEISi inhibitor that inhibits the meis luciferase reporter gene in vitro and induces MEIS-dependent hematopoietic stem cell maintenance and self-renewal, which can be used in research areas such as cardiac injury, hematopoietic problems, bone marrow transplantation and cancer. |
| In vitro | In studies of neonatal rat cardiomyocytes (RNCMs) and human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes, treatment with MEISi-2 (5 μM) was performed. In RNCMs, the proportion of cells positive for the proliferation markers phospho-histone H3 (Ph3) and Aurora B significantly increased following treatment. Specifically, the proliferation rate of Ph3⁺/TnnT2⁺ cells increased by up to 4.5-fold, while the proportion of Aurora B⁺/TnnT2⁺ cells doubled. Meanwhile, the expression levels of MEIS1 target genes, including Hif-1α, Hif-2α, and p21, were significantly downregulated [1]. |
| In vivo | In a mouse model, MEISi-2 (at a concentration of 10µM) was administered intraperitoneally on days 1, 4, and 7 (100µL per injection), and bone marrow cells were collected on day 10 for analysis. The Results showed that this treatment significantly upregulated the expression of hematopoietic stem cell markers c-Kit+ and Sca-1+, with the numbers of c-Kit+, Sca-1+, and LSKCD34lowHSC cells increasing approximately 2-fold, 1.5-fold, and 3-fold, respectively. Meanwhile, MEISi-2 treatment downregulated the expression of key cell cycle inhibitors such as Meis1, Hif-2α, and p16. The study indicates that MEISi-2 effectively inhibits MEIS protein function and promotes an increase in hematopoietic stem cell numbers by modulating gene expression[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (261.16 mM), Sonication is recommended.
|
| Keywords | transplantations | TALE | MEISi-2 | MEISi 2 | meis1 | MEIS | marrow | issues | injuries | Inhibitor | inhibit | hematopoiesis | cardiac | cancer | bone | Benzoic acid, 4-hydroxy-, 2-[(Z)-(2-oxo-1(2H)-naphthalenylidene)methyl]hydrazide |
| Related Compound Libraries | Bioactive Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
